Mike Nally is the Chief Executive Officer of Generate:Biomedicines. Mike's expertise in leading global organizations has been instrumental in the company's efforts to make protein therapeutics programmable. Under his leadership, the company successfully completed its Series B and C financing rounds and has raised more than $750 million since inception. These funding milestones have enabled the advancement of Generate:Biomedicines’ pioneering work in generative AI and a robust pipeline of protein therapeutics with two clinical assets and more than 15 preclinical candidates.